JP2018504418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504418A5 JP2018504418A5 JP2017539669A JP2017539669A JP2018504418A5 JP 2018504418 A5 JP2018504418 A5 JP 2018504418A5 JP 2017539669 A JP2017539669 A JP 2017539669A JP 2017539669 A JP2017539669 A JP 2017539669A JP 2018504418 A5 JP2018504418 A5 JP 2018504418A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- cancer
- compound
- represented
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 49
- 206010028980 Neoplasm Diseases 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 29
- 101800003838 Epidermal growth factor Proteins 0.000 claims 29
- 229940116977 epidermal growth factor Drugs 0.000 claims 29
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 24
- 229940121647 egfr inhibitor Drugs 0.000 claims 19
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 18
- 125000002252 acyl group Chemical group 0.000 claims 18
- 125000000524 functional group Chemical group 0.000 claims 18
- 150000004677 hydrates Chemical class 0.000 claims 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 18
- 230000003287 optical effect Effects 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 13
- 229960005395 cetuximab Drugs 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 229960001972 panitumumab Drugs 0.000 claims 11
- 229960001686 afatinib Drugs 0.000 claims 10
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 10
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 9
- 229960001433 erlotinib Drugs 0.000 claims 9
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 9
- 229960003278 osimertinib Drugs 0.000 claims 9
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 6
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000005787 hematologic cancer Diseases 0.000 claims 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 4
- 238000009169 immunotherapy Methods 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000003747 lymphoid leukemia Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 102100026882 Alpha-synuclein Human genes 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 108010065524 CD52 Antigen Proteins 0.000 claims 3
- 102000013135 CD52 Antigen Human genes 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims 2
- 229950004272 brigatinib Drugs 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- 229950008835 neratinib Drugs 0.000 claims 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 2
- 229960002450 ofatumumab Drugs 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 230000001235 sensitizing effect Effects 0.000 claims 2
- 229960005267 tositumomab Drugs 0.000 claims 2
- 229960000241 vandetanib Drugs 0.000 claims 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 230000007761 synergistic anti-cancer Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 C*(C)c1c(C(NC(C2=C(*)c3c(*)c(*)c(*)c(*)c3*2)=S)=*)c(*)c(*)c(*)c1* Chemical compound C*(C)c1c(C(NC(C2=C(*)c3c(*)c(*)c(*)c(*)c3*2)=S)=*)c(*)c(*)c(*)c1* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021011512A JP7624700B2 (ja) | 2015-02-05 | 2021-01-27 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112257P | 2015-02-05 | 2015-02-05 | |
| US62/112,257 | 2015-02-05 | ||
| US201562136530P | 2015-03-22 | 2015-03-22 | |
| US62/136,530 | 2015-03-22 | ||
| PCT/IL2016/050134 WO2016125169A1 (en) | 2015-02-05 | 2016-02-04 | Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021011512A Division JP7624700B2 (ja) | 2015-02-05 | 2021-01-27 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018504418A JP2018504418A (ja) | 2018-02-15 |
| JP2018504418A5 true JP2018504418A5 (enExample) | 2019-03-14 |
Family
ID=56563560
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539669A Pending JP2018504418A (ja) | 2015-02-05 | 2016-02-04 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
| JP2021011512A Active JP7624700B2 (ja) | 2015-02-05 | 2021-01-27 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
| JP2023027482A Pending JP2023062187A (ja) | 2015-02-05 | 2023-02-24 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021011512A Active JP7624700B2 (ja) | 2015-02-05 | 2021-01-27 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
| JP2023027482A Pending JP2023062187A (ja) | 2015-02-05 | 2023-02-24 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10912745B2 (enExample) |
| EP (2) | EP3750530B1 (enExample) |
| JP (3) | JP2018504418A (enExample) |
| KR (1) | KR20170109589A (enExample) |
| CN (3) | CN112353938A (enExample) |
| AU (2) | AU2016213972B2 (enExample) |
| ES (2) | ES3064856T3 (enExample) |
| IL (2) | IL253797B (enExample) |
| WO (1) | WO2016125169A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| AU2017269335B2 (en) | 2016-05-26 | 2021-07-01 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| SG11201906412SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Pyridine compounds as allosteric shp2 inhibitors |
| BR112019015075A2 (pt) | 2017-01-23 | 2020-03-10 | Revolution Medicines, Inc. | Compostos bicíclicos como inibidores de shp2 alostéricos |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| JP7356414B2 (ja) | 2017-09-07 | 2023-10-04 | レヴォリューション・メディスンズ，インコーポレイテッド | がんを治療するためのｓｈｐ２阻害剤組成物および方法 |
| SG11202002941WA (en) | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| EP3710050A4 (en) * | 2017-11-16 | 2021-06-16 | TyrNovo Ltd. | COMBINATIONS OF IRS / STAT3 DOUBLE MODULATORS AND ANTI-PD-1 / PD-L1 AMBODIES FOR TREATMENT OF CANCER |
| US20200325543A1 (en) * | 2017-11-20 | 2020-10-15 | Tolremo Therapeutics Ag | Diagnostic method |
| CA3084058A1 (en) | 2017-12-15 | 2019-06-20 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
| EP4470621A3 (en) | 2018-03-19 | 2025-05-07 | Taiho Pharmaceutical Co., Ltd. | Use of sodium alkyl sulfate |
| CA3094108A1 (en) * | 2018-03-27 | 2019-10-03 | Board Of Regents, The University Of Texas Systems | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
| CA3105333A1 (en) | 2018-07-10 | 2020-01-16 | Sanofi | Combination therapies against cancer targeting cd38 and tgf-beta |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| WO2020055761A1 (en) * | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| AU2019341976A1 (en) * | 2018-09-18 | 2021-04-15 | General Incorporated Association Pharma Valley Project Supporting Organization | Cancer combination therapy using quinoline carboxamide derivative |
| CN109675040B (zh) * | 2018-12-31 | 2021-07-30 | 清华大学 | 治疗乳腺癌的组合物及其应用 |
| US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
| WO2020236502A1 (en) * | 2019-05-22 | 2020-11-26 | Clear Creek Bio, Inc. | Combination therapies for cancer treatment |
| CN115466205B (zh) * | 2021-11-04 | 2023-10-24 | 特尔诺沃有限公司 | 分离的3-（2-溴-3,4-二羟基-苯基）-n-（3,4,5-三羟基-苄基）-硫代丙烯酰胺的反式异构体 |
| WO2023086927A1 (en) * | 2021-11-11 | 2023-05-19 | Vanderbilt University | Combined targeting of stat3 and ulk1 to treat glioblastoma |
| KR20240086554A (ko) | 2022-12-09 | 2024-06-18 | 재단법인대구경북과학기술원 | 올무티닙을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| CN1155977A (zh) | 1995-08-28 | 1997-08-06 | 化学工业部沈阳化工研究院 | 含氟二苯基丙烯酰胺类杀菌剂 |
| CN1043720C (zh) | 1995-08-28 | 1999-06-23 | 化学工业部沈阳化工研究院 | 含氟二苯基丙烯酰胺类杀菌剂 |
| JP4073489B2 (ja) | 1996-05-24 | 2008-04-09 | ニューロサーチ・アクティーゼルスカブ | 酸性基を有するフエニル誘導体、その製造方法及びそれをクロライドチャンネル遮断剤として使用する方法 |
| WO1997045111A1 (en) | 1996-05-24 | 1997-12-04 | Neurosearch A/S | Phenyl derivatives useful as blockers of chloride channels |
| US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| US6020332A (en) | 1997-02-20 | 2000-02-01 | Shenyang Research Institute Of Chemical Industry | Fluorine-containing diphenyl acrylamide antimicrobial agents |
| EP0860438B1 (en) | 1997-02-21 | 2003-01-08 | Shenyang Research Institute of Chemical Industry | Fluorine-containing diphenyl acrylamide antimicrobial agents |
| AU1457299A (en) | 1997-11-12 | 1999-05-31 | Ariad Pharmaceuticals, Inc. | Novel signal transduction inhibitors, compositions containing them |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6455587B1 (en) | 2000-03-15 | 2002-09-24 | Pharmacor Inc. | Amino acid derivatives as HIV aspartyl protease inhibitors |
| IL159270A0 (en) | 2001-06-14 | 2004-06-01 | Yissum Res Dev Co | Non-myeloablative tolerogenic treatment with tyrphostins |
| CA2477585A1 (en) | 2001-11-21 | 2003-06-05 | Elan Pharmaceuticals, Inc. | Amino acid derivatives useful for the treatment of alzheimer's disease |
| JP4511183B2 (ja) | 2001-12-10 | 2010-07-28 | デュ，ヤンシェン | 神経変性疾患および心臓血管疾患の治療 |
| MXPA03000966A (es) | 2002-02-28 | 2003-09-04 | Pfizer Prod Inc | Agentes antidiabeticos. |
| WO2003101927A1 (en) | 2002-05-31 | 2003-12-11 | Proteotech, Inc. | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease |
| US20040209930A1 (en) * | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US20060047171A1 (en) | 2003-12-22 | 2006-03-02 | Harold Meckler | Catalytic hydrogenation of nitriles to produce capsaicinoid derivatives and amine compounds, and methods for purifying and obtaining the polymorphs thereof |
| KR100683274B1 (ko) | 2004-02-12 | 2007-02-15 | 에스케이케미칼주식회사 | 치환된 벤조피란 화합물의 제조방법 |
| WO2007072041A1 (en) | 2005-12-23 | 2007-06-28 | Astex Therapeutics Limited | Therapeutic compounds |
| WO2008028314A1 (fr) | 2006-08-07 | 2008-03-13 | Lotus Pharmaceutical Co., Ltd. | Dérivés de catéchol, composition et application associées |
| US20120083528A1 (en) | 2006-12-04 | 2012-04-05 | Novotyr Therapeutics Ltd. | Novel protein kinase modulators and therapeutic uses thereof |
| EP2125712B1 (en) * | 2006-12-04 | 2014-07-23 | Novotyr Therapeutics Ltd. | Novel protein kinase modulators and therapeutic uses thereof |
| EP2285774B1 (en) * | 2008-06-05 | 2015-02-25 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Novel modulators of protein kinase signaling |
| US9073880B2 (en) | 2010-12-27 | 2015-07-07 | Yissum Research Development Company of the Hebrew University of Jeruselem Ltd. | 2-(2-phenylethenyl) 1,3-benzodiazepine derivatives useful for the treatment of cancer |
| WO2012117396A1 (en) * | 2011-03-01 | 2012-09-07 | Novotyr Therapeutics Ltd | Tyrphostin derivative in combination with cytotoxic compounds for treating cancer |
| US8980259B2 (en) * | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
| EP2999465A1 (en) * | 2013-05-21 | 2016-03-30 | Synta Pharmaceuticals Corp. | Specific cancer treatment regimens with ganetespib |
-
2016
- 2016-02-04 JP JP2017539669A patent/JP2018504418A/ja active Pending
- 2016-02-04 AU AU2016213972A patent/AU2016213972B2/en active Active
- 2016-02-04 CN CN202011245500.3A patent/CN112353938A/zh active Pending
- 2016-02-04 KR KR1020177023283A patent/KR20170109589A/ko not_active Ceased
- 2016-02-04 ES ES20168234T patent/ES3064856T3/es active Active
- 2016-02-04 ES ES16746247T patent/ES2808781T3/es active Active
- 2016-02-04 US US15/548,915 patent/US10912745B2/en active Active
- 2016-02-04 EP EP20168234.1A patent/EP3750530B1/en active Active
- 2016-02-04 EP EP16746247.2A patent/EP3253733B1/en active Active
- 2016-02-04 CN CN202011245496.0A patent/CN112494653A/zh active Pending
- 2016-02-04 CN CN201680008809.6A patent/CN107250108B/zh active Active
- 2016-02-04 WO PCT/IL2016/050134 patent/WO2016125169A1/en not_active Ceased
-
2017
- 2017-08-02 IL IL253797A patent/IL253797B/en active IP Right Grant
-
2020
- 2020-10-08 AU AU2020250235A patent/AU2020250235A1/en not_active Abandoned
-
2021
- 2021-01-24 IL IL280378A patent/IL280378B/en unknown
- 2021-01-27 US US17/159,798 patent/US12201592B2/en active Active
- 2021-01-27 JP JP2021011512A patent/JP7624700B2/ja active Active
-
2023
- 2023-02-24 JP JP2023027482A patent/JP2023062187A/ja active Pending
-
2025
- 2025-01-02 US US19/007,840 patent/US20250134837A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nagelkerke et al. | Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy | |
| TWI794171B (zh) | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 | |
| JP2019501204A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2014034576A5 (enExample) | ||
| CN120285177A (zh) | Hdac抑制剂和pd-1抑制剂的组合疗法 | |
| JP2020536971A5 (enExample) | ||
| JP2010522194A5 (enExample) | ||
| JP2009514881A5 (enExample) | ||
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| JP2019535746A5 (enExample) | ||
| JP2014508782A5 (enExample) | ||
| JP2018534289A5 (enExample) | ||
| US20180085341A1 (en) | Methods for treating cancer | |
| RU2013132018A (ru) | Применение производных пиримидина для лечения egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, направленным против членов семейства egfr | |
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| WO2018229130A1 (en) | Compounds for treating tnbc | |
| KR20210019116A (ko) | 카복시아미도트리아졸 오로테이트를 사용하여 화학치료제 및 표적화된 약물에 대해 내성을 획득한 암을 치료하기 위한 방법 및 조성물 | |
| US10646464B2 (en) | Methods for treating cancer | |
| JP2021512046A5 (enExample) | ||
| RU2017105817A (ru) | Комбинированная терапия | |
| CN106255500B (zh) | 用于治疗癌症的新的头孢菌素衍生物 | |
| JP2019519573A (ja) | がんを処置するための方法 | |
| JP2022502399A5 (enExample) | ||
| US20180250260A1 (en) | Methods for treating cancer |